Cardiology CNE/CPE/CME Course 5 | Novel Agents Targeting the Source of HCM Disease
About Course
Program Description
Treatment guidelines include recommendations on recently approved medications and discussions of recent clinical trial data on monotherapy and combination treatment options for pulmonary arterial hypertension (PAH). Current and emerging management strategies target new pathways and treatment targets. This foundational activity provides nurses with a high-level overview of treatment pathways and therapeutic targets for the management of PAH.
Educational Objectives
Upon completion, participants should be able to:
- Review the pathophysiology, diagnostic criteria, and classification of PAH.
- Identify the classes and associated side effects of medications used to treat PAH.
- Summarize new treatment pathways and emerging therapeutic targets in the management of PAH.
- Recognize the potential for remote monitoring via telehealth in patients with PAH.
Intended Audience
The intended audience includes nurse practitioners, nurses, physician assistants and other providers involved in the management of patients with PAH.
Commercial Supporter
This activity is supported by an independent medical education grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Max Credits
- 1.00 / AAPA Category 1 CME Credit
- 1.00 / AANP Contact Hour
- 1.00 / ANCC Contact Hour
Expires: May 14, 2023
